« Return to News | Clinical Intelligence

FDA approves first surgical treatment to remove cellulite

Wednesday, February 1, 2012 03:30 PM

The FDA has approved Cellulaze, a single-treatment laser that affects the physiological structure of cellulite. Cellulaze, which previously gained approval in the U.K., was developed by Cynosure, a global aesthetic laser manufacturer and creator of the SmartLipo laser.

"Cellulaze is the world's first surgical treatment for cellulite designed to treat women who have struggled to eliminate cellulite through diet and exercise," said Cynosure president and CEO Michael Davin.

Unlike temporary, non-invasive treatments on the market, Cellulaze is the only aesthetic device that directly treats the physiological structure of cellulite, with clinically proven results. In the U.S. alone, patient trials have demonstrated that after two years post-procedure no cellulite has returned to the areas treated.

Four years of clinical data has demonstrated that Cellulaze treatments can increase the thickness of the skin by 25% and increase the elasticity of the skin by 29% at one year.

"We have been extremely fortunate that in Europe the Cellulaze laser treatment has CE mark approval prior to the awaiting FDA approval,” said Neil Wolfenden, Cynosure U.K. managing director. “To-date we have witnessed high patient satisfaction across the board, and impressive national press coverage.”

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.